Which has preferable valuation & earnings, GHRS or SRRK?

GH Research is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is GHRS or SRRK more profitable?

GH Research's return on equity of -19.36% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Scholar Rock N/A -163.52% -96.67%

Which has preferable earnings & valuation, APGE or GHRS?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is APGE or GHRS more profitable?

GH Research's return on equity of -19.36% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% GH Research N/A -19.36% -18.73%

Is CGON or GHRS more profitable?

GH Research's return on equity of -19.36% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% GH Research N/A -19.36% -18.73%

Which has higher earnings & valuation, GRFS or GHRS?

Grifols has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.57 $454.82M $0.19 37.79 GH Research N/A N/A -$48.26M -$0.92 N/A

Is GRFS or GHRS more profitable?

Grifols has a net margin of 5.54% compared to GH Research's net margin of 0.00%. Grifols' return on equity of 6.21% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% GH Research N/A -19.36% -18.73%

GH Research (GHRS) Competitors

$23.61 +1.52 (+6.88%)

Closing price 04:00 PM Eastern

Extended Trading

$23.14 -0.47 (-1.99%)

As of 07:52 PM Eastern

Compare

GHRS vs. SRRK, APGE, TWST, CGON, and GRFS

Should you buy GH Research stock or one of its competitors? MarketBeat compares GH Research with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GH Research include Scholar Rock (SRRK), Apogee Therapeutics (APGE), Twist Bioscience (TWST), CG Oncology (CGON), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does GH Research compare to Scholar Rock?

GH Research (NASDAQ:GHRS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

GH Research has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Scholar Rock had 5 more articles in the media than GH Research. MarketBeat recorded 5 mentions for Scholar Rock and 0 mentions for GH Research. Scholar Rock's average media sentiment score of 1.57 beat GH Research's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
GH Research	Neutral
Scholar Rock	Very Positive

56.9% of GH Research shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GH Research's return on equity of -19.36% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Scholar Rock	N/A	-163.52%	-96.67%

GH Research is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

GH Research presently has a consensus price target of $40.38, suggesting a potential upside of 71.01%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 9.23%. Given GH Research's higher possible upside, equities research analysts clearly believe GH Research is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

Scholar Rock beats GH Research on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

GH Research's return on equity of -19.36% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
GH Research	N/A	-19.36%	-18.73%

Apogee Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Apogee Therapeutics presently has a consensus target price of $119.67, suggesting a potential downside of 9.94%. GH Research has a consensus target price of $40.38, suggesting a potential upside of 71.01%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.30
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Apogee Therapeutics had 34 more articles in the media than GH Research. MarketBeat recorded 34 mentions for Apogee Therapeutics and 0 mentions for GH Research. Apogee Therapeutics' average media sentiment score of 0.61 beat GH Research's score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Apogee Therapeutics	Positive
GH Research	Neutral

Apogee Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

GH Research beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

How does GH Research compare to Twist Bioscience?

GH Research (NASDAQ:GHRS) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

GH Research has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Twist Bioscience	$376.57M	14.06	-$77.67M	-$1.33	N/A

GH Research currently has a consensus target price of $40.38, indicating a potential upside of 71.01%. Twist Bioscience has a consensus target price of $71.60, indicating a potential downside of 15.76%. Given GH Research's higher possible upside, analysts clearly believe GH Research is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Twist Bioscience had 6 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Twist Bioscience and 0 mentions for GH Research. Twist Bioscience's average media sentiment score of 1.02 beat GH Research's score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
GH Research	Neutral
Twist Bioscience	Positive

56.9% of GH Research shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GH Research has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. GH Research's return on equity of -19.36% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

GH Research beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 5 more articles in the media than GH Research. MarketBeat recorded 5 mentions for CG Oncology and 0 mentions for GH Research. CG Oncology's average media sentiment score of 1.02 beat GH Research's score of 0.00 indicating that CG Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
CG Oncology	Positive
GH Research	Neutral

CG Oncology presently has a consensus price target of $81.73, indicating a potential upside of 24.34%. GH Research has a consensus price target of $40.38, indicating a potential upside of 71.01%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

CG Oncology has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

GH Research has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,435.00	-$160.99M	-$2.33	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

GH Research's return on equity of -19.36% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
GH Research	N/A	-19.36%	-18.73%

Summary

GH Research beats CG Oncology on 8 of the 13 factors compared between the two stocks.

How does GH Research compare to Grifols?

Grifols (NASDAQ:GRFS) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Grifols currently has a consensus price target of $10.00, suggesting a potential upside of 39.28%. GH Research has a consensus price target of $40.38, suggesting a potential upside of 71.01%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Grifols has a net margin of 5.54% compared to GH Research's net margin of 0.00%. Grifols' return on equity of 6.21% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
GH Research	N/A	-19.36%	-18.73%

56.9% of GH Research shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Grifols has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.57	$454.82M	$0.19	37.79
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

In the previous week, Grifols had 4 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Grifols and 0 mentions for GH Research. Grifols' average media sentiment score of 0.39 beat GH Research's score of 0.00 indicating that Grifols is being referred to more favorably in the media.

Company	Overall Sentiment
Grifols	Neutral
GH Research	Neutral

Grifols has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

Grifols beats GH Research on 10 of the 15 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.52B	$3.45B	$6.46B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-25.66	20.09	24.71	24.00
Price / Sales	N/A	188.30	492.47	90.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	5.24	8.28	10.82	6.53
Net Income	-$48.26M	$23.85M	$3.56B	$336.99M
7 Day Performance	18.17%	5.21%	1.67%	-0.22%
1 Month Performance	6.74%	2.19%	0.43%	0.77%
1 Year Performance	102.14%	60.99%	32.84%	31.57%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	2.4409 of 5 stars	$23.61 +6.9%	$40.38 +71.0%	+79.4%	$1.52B	N/A	N/A	10
SRRK Scholar Rock	2.1202 of 5 stars	$44.91 -2.2%	$56.00 +24.7%	+44.5%	$5.38B	N/A	N/A	140	Positive News
APGE Apogee Therapeutics	1.4591 of 5 stars	$84.95 -1.4%	$114.56 +34.9%	+215.9%	$5.25B	N/A	N/A	91	Trending News Analyst Downgrade Options Volume
TWST Twist Bioscience	1.9759 of 5 stars	$84.91 +5.1%	$71.60 -15.7%	+145.9%	$5.24B	$376.57M	N/A	990	Positive News Gap Down
CGON CG Oncology	3.0991 of 5 stars	$59.33 -0.4%	$81.73 +37.8%	+159.3%	$5.23B	$4.04M	N/A	61	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. SRRK, APGE, TWST, CGON, and GRFS

How does GH Research compare to Scholar Rock?

Summary

How does GH Research compare to Apogee Therapeutics?

Summary

How does GH Research compare to Twist Bioscience?

Summary

How does GH Research compare to CG Oncology?

Summary

How does GH Research compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. SRRK, APGE, TWST, CGON, and GRFS

How does GH Research compare to Scholar Rock?

Which has more risk & volatility, GHRS or SRRK?

Does the media prefer GHRS or SRRK?

Do insiders & institutionals hold more shares of GHRS or SRRK?

Is GHRS or SRRK more profitable?

Which has preferable valuation & earnings, GHRS or SRRK?

Do analysts prefer GHRS or SRRK?

Summary

How does GH Research compare to Apogee Therapeutics?

Is APGE or GHRS more profitable?

Which has preferable earnings & valuation, APGE or GHRS?

Do analysts rate APGE or GHRS?

Do insiders and institutionals hold more shares of APGE or GHRS?

Does the media prefer APGE or GHRS?

Which has more risk & volatility, APGE or GHRS?

Summary

How does GH Research compare to Twist Bioscience?

Which has more risk and volatility, GHRS or TWST?

Which has better valuation and earnings, GHRS or TWST?

Do analysts rate GHRS or TWST?

Does the media prefer GHRS or TWST?

Do insiders & institutionals believe in GHRS or TWST?

Is GHRS or TWST more profitable?

Summary

How does GH Research compare to CG Oncology?

Do insiders and institutionals believe in CGON or GHRS?

Does the media refer more to CGON or GHRS?

Do analysts prefer CGON or GHRS?

Which has more volatility & risk, CGON or GHRS?

Which has better earnings and valuation, CGON or GHRS?

Is CGON or GHRS more profitable?

Summary

How does GH Research compare to Grifols?

Do analysts rate GRFS or GHRS?

Is GRFS or GHRS more profitable?

Do institutionals and insiders hold more shares of GRFS or GHRS?

Which has higher earnings & valuation, GRFS or GHRS?

Does the media favor GRFS or GHRS?

Which has more volatility & risk, GRFS or GHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools